Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020' provides Erbitux sales forecasts for
US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and
analysis of sales performance during the forecast period (2014-2020). The report also includes information on Oncology's Disease
market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary
research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company
and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US and EU5
- Analysis and review of Erbitux including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Erbitux including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2014-2020 for Erbitux in each of the US and EU5 markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3
2 Introduction 4
2.1 Gastric Cancer Market 4

Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020 (From Slideshare) Page 1/5


2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6
3 Gastric Cancer Disease: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts and CAGR 7
3.3 Drivers for the Gastric Cancer Disease Market 7
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9
4 Tumor Node Metastases(TNM) Classification of gastric cancer 10
5 Erbitux 13
5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Approval History of Erbitux 14
5.5 Factors Affecting Sales of Erbitux 14
5.5.1 Gastric Cancer Market 14
5.5.2 High Efficacy 14
5.5.3 Beneficial for both Operable and Inoperable Therapy 14
5.5.4 Highly Expensive and Toxic Compared to Competitor 14
5.5.5 Presence in Market Prior to Gastric Cancer 15
5.5.6 Average Competition 15
5.6 Drug Risk Benefit Score 15
5.6.1 Efficacy 15
5.6.2 Safety 15
5.6.3 Compliance 16
5.6.4 Dosing Convenience 16
5.7 Intensity of Competition 16
5.8 Sales forecast 16
5.8.1 Target patient Pool of Erbitux 16
5.8.2 Dosing 17
5.8.3 Market Penetration 17
5.8.4 Annual Cost of Therapy 17
5.8.5 Sales Projections of Erbitux 18
6 Gastric Cancer Market: Appendix 25
6.1 Market Definitions 25
6.2 List of Abberiviations 25
6.3 Research Methodology 25
6.3.1 Coverage 25
6.3.2 Secondary Research 25
6.3.3 Forecasting 26
6.3.4 Number of Patients Approved to take the Drug 26
6.3.5 Net Penetration of Drug 26
6.3.6 Net Annual Dosing 26
6.3.7 Annual Cost of Therapy 27
6.3.8 Primary Research 27
6.3.9 Expert Panels 27



6.4 Contact Us 27
6.5 Disclaimer 27
6.6 Sources 27

1.1 List of Tables

Table 1: Gastric Cancer, Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Market Size Forecast ($bn), 2009'2020 7
Table 3: Approval History of Erbitux 14
Table 4: Drug Risk Benefit Score of Erbitux 15
Table 5: Annual Cost of Therapy 18
Table 6: Gastric Cancer, Global, Sales Forecast of Erbitux ($m) 2014-2020 19
Table 7: Gastric Cancer, the US, Sales Forecast of Erbitux ($m) 2014-2020 20
Table 8: Gastric Cancer, the UK, Sales Forecast of Erbitux ($m) 2014-2020 21
Table 9: Gastric Cancer, France, Sales Forecast of Erbitux ($m) 2014-2020 22
Table 10: : Gastric Cancer, Germany, Sales Forecast of Erbitux ($m) 2014-2020 23
Table 11: Gastric Cancer, Italy, Sales Forecast of Erbitux ($m) 2014-2020 24
Table 12: Gastric Cancer, Spain, Sales Forecast of Erbitux ($m) 2014-2020 25

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) '(% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: Gastric Cancer, Global, Market Size Forecast ($bn), 2009'2020 7
Figure 5: Oncology, Global, Incidence (in millions), 2008-2030 8
Figure 6: Gastric Cancer, Global, Incidence (in millions), 2008-2030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Erbitux in the US and EU 17
Figure 13: Gastric Cancer, Global, Sales Forecast of Erbitux ($m) 2014-2020 18
Figure 14: Gastric Cancer, the US and EU, Erbitux Sales Distribution, 2014 19
Figure 15: Gastric Cancer, the US, Sales Forecast of Erbitux ($m) 2014-2020 20
Figure 16: Gastric Cancer, the UK, Sales Forecast of Erbitux ($m) 2014-2020 21
Figure 17: Gastric Cancer, France, Sales Forecast of Erbitux ($m) 2014-2020 22
Figure 18: Gastric Cancer, Germany, Sales Forecast of Erbitux ($m) 2014-2020 23
Figure 19: Gastric Cancer, Italy, Sales Forecast of Erbitux ($m) 2014-2020 24
Figure 20: Gastric Cancer, Spain, Sales Forecast of Erbitux ($m) 2014-2020 25


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Erbitux (Gastric Cancer)- Analysis and Forecasts to 2020